Deucravacitinib (BMS-986165) in the Treatment of Pityriasis Rubra Pilaris
Mayo Clinic
Summary
The purpose of this study is to evaluate the safety and effectiveness of Deucravacitinib (BMS-986165) in Pityriasis Rubra Pilaris as assessed by the change in Investigator Global Assessment (IGA), PASI- 50, 75, 90, DLQI, NRS itch, and Skindex-16 at week 24. To predict responses through the identification of unique biomarkers of PRP utilizing single-cell RNA sequencing.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Written informed consent must be obtained before any assessment is performed. * Female and male patients ≥ 18 years of age. * Subjects must have a diagnosis of PRP type 1, 2. * Biopsy result consistent with PRP and not diagnostic for another disease. * Moderate to severe disease defined as Psoriasis Area and Severity Index (PASI) ≥ 10. * Candidates for systemic therapy. * Inadequate response to or not suitable for topical therapy in the opinion of the investigator. * If using any of the allowed topical treatments on the affected areas, the dose and application frequency…
Interventions
- DrugDeucravacitinib
6 mg administered orally twice daily for 24 weeks.
Location
- Mayo Clinic in ArizonaScottsdale, Arizona